GW-0724 is a small molecule compound being investigated as a selective agonist of the PPARδ receptor (PPARβ/δ). In laboratory models, it has been associated with the regulation of fatty acid oxidation, metabolic flexibility, and skeletal muscle endurance performance.
Contents
Unspecified (oral capsule form)
Concentration (test)
Unspecified
Packaging
Sealable packaging (capsules)
Storage
Store in a dry place, at room temperature, away from light.
Molecular formula
Unspecified
Molecular weight
Unspecified
Other names
GW-0724, GW0724, selective PPARδ agonist
In laboratory studies, GW-0724 has been linked to research in areas such as:
- increasing β-oxidation of fatty acids and metabolic flexibility,
- endurance performance and resistance to fatigue,
- adjustment of lipid profile and energy metabolism,
- insulin sensitivity and glucose homeostasis,
- mitochondrial bioenergetics of skeletal muscle.
This content is for educational purposes only. It is not a recommendation for human use. The substance is intended for laboratory research only.
What is GW-0724
GW-0724 is an experimental selective agonist of PPARδ (PPARβ/δ), a nuclear receptor family that regulates the expression of genes involved in fatty acid transport and oxidation, energy production, and muscle adaptation. It is being studied in model systems for its potential to promote aerobic capacity and metabolic efficiency.
It is a lipophilic small molecule with the aim of influencing transcriptional programs related to energy metabolism. Its impact on glucose metabolism and lipid parameters is also being investigated in experiments.
Research is limited to laboratory settings; it is not an approved substance for therapeutic use.
How GW-0724 works
Activation of PPARδ regulates genes involved in the transport of fatty acids into mitochondria and their β-oxidation (e.g. CPT1, PDK4), which promotes the use of fats as an energy source and conserves glycogen.
In experiments, crosstalk with mitochondrial biogenesis (e.g., via PGC-1α pathways) and a shift of muscle fibers towards more oxidative phenotypes are observed, which may be related to endurance performance.
Changes in markers of inflammation and lipid profile are also being investigated, which may reflect improved metabolic flexibility under model conditions.
Researched effects and interesting facts
-
Fatty acid oxidation: Promoting β-oxidation and the use of fats as a primary fuel.
-
Endurance: Evidence from models suggests a possible increase in aerobic capacity and a delay in the onset of fatigue.
-
Lipid profile: The effect on triacylglycerols and other lipid indicators is monitored.
-
Glucose homeostasis: Possible improvement in insulin sensitivity depending on the protocol.
-
Mitochondria: Indications for improving the efficiency of skeletal muscle bioenergetics.
Dosage in studies
The values listed are derived solely from research studies and are not intended for real-world use outside of a laboratory environment.
-
Dose: 5–20 mg daily (model oral protocols)
-
Form: oral (capsules)
-
Frequency: 1x daily according to study objective
-
Duration: 4 – 8 weeks within experimental protocols
Possible side effects
- Dyspeptic complaints (nausea, discomfort in the digestive tract)
- Headaches or restlessness (individual depending on protocol)
- Class-specific concerns with PPARδ agonists observed in preclinical models
Resources
- Review papers on PPARδ agonists and metabolic flexibility (experimental studies)
- Publications on β-oxidation regulation and CPT1/PDK4 genes (model systems)
- Studies focusing on endurance and muscle metabolism after PPARδ activation
- Literature on mitochondrial biogenesis and PGC-1α in skeletal muscle
- Methodological protocols for oral dosage regimens in capsule form
This article is for informational purposes only. It does not constitute a recommendation or solicitation for use. The information provided is a summary of existing scientific literature and is for educational purposes only.
Sale
